Wormser Freres Gestion Has $873,000 Holdings in Abbott Laboratories $ABT

Wormser Freres Gestion lifted its stake in Abbott Laboratories (NYSE:ABT) by 1,798.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,968 shares of the healthcare product maker’s stock after buying an additional 6,601 shares during the quarter. Abbott Laboratories makes up about 0.5% of Wormser Freres Gestion’s holdings, making the stock its 22nd biggest holding. Wormser Freres Gestion’s holdings in Abbott Laboratories were worth $873,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. American National Bank of Texas raised its holdings in shares of Abbott Laboratories by 2.4% in the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after buying an additional 79 shares in the last quarter. Nia Impact Advisors LLC increased its holdings in Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares in the last quarter. Connable Office Inc. increased its holdings in Abbott Laboratories by 0.5% during the 3rd quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker’s stock valued at $2,015,000 after purchasing an additional 81 shares in the last quarter. Park Place Capital Corp increased its holdings in Abbott Laboratories by 11.0% during the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after purchasing an additional 81 shares in the last quarter. Finally, Lantern Wealth Advisors LLC increased its holdings in Abbott Laboratories by 1.7% during the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock valued at $674,000 after purchasing an additional 84 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott recently secured FDA and EU approval for its AI-powered Ultreon 3.0 tool, which could support growth in its cardiovascular imaging business and add to its medical technology momentum. Article Title
• Positive Sentiment: Abbott also obtained CE mark clearance for its Libre Duo glucose-ketone monitor, expanding its diabetes technology lineup and reinforcing innovation in one of its key growth categories. Article Title
• Neutral Sentiment: Recent coverage highlighting strong Wall Street views on Abbott suggests analysts remain constructive on the stock’s long-term prospects, but the articles do not point to a new upgrade or a near-term earnings catalyst. Article Title
• Neutral Sentiment: Zacks noted that investors have been searching for Abbott more heavily, which can reflect increased interest, but does not by itself change the company’s fundamentals. Article Title
• Negative Sentiment: One comparison piece argued Boston Scientific may offer more upside than Abbott, which can weigh on ABT sentiment by implying investors may prefer a rival medtech name right now. Article Title

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ABT shares. Barclays lowered their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research note on Monday, April 20th. Bank of America lowered their target price on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Mizuho lowered their target price on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. BTIG Research reissued a “buy” rating and issued a $131.00 target price on shares of Abbott Laboratories in a research note on Monday, April 27th. Finally, Evercore lowered their target price on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $119.09.

Abbott Laboratories Stock Down 1.1%

NYSE:ABT opened at $85.36 on Friday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $148.68 billion, a P/E ratio of 23.91, a P/E/G ratio of 1.43 and a beta of 0.65. The stock’s fifty day simple moving average is $94.46 and its 200-day simple moving average is $110.69.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period last year, the company earned $1.09 EPS. The firm’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Buying and Selling

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president owned 24,628 shares of the company’s stock, valued at $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.